Skip to main content

Osteoarthritis

Medications

20-12-2022 | Osteoarthritis | News

Support for further investigation of metformin in people with osteoarthritis

Metformin use is associated with a significant reduction in the risk for total knee or hip replacement among people with type 2 diabetes, shows research published in CMAJ.

03-06-2022 | EULAR 2022 | Conference coverage | News

OKINADA trial: No improvement in knee osteoarthritis symptoms with TNF inhibition

The tumor necrosis factor inhibitor adalimumab does not improve pain or function in people with knee osteoarthritis, indicate phase 2 trial results.

19-04-2022 | Osteoarthritis | News

Intramuscular glucocorticoid injection ‘considered effective’ for knee OA pain

Intramuscular glucocorticoid injection is noninferior to intra-articular injection for reducing knee pain after 8 and 24 weeks in patients with knee osteoarthritis, but may be inferior at 4 weeks, research shows.

08-04-2022 | Osteoarthritis | News

Ultrasound-guided hip injection may benefit people with hip osteoarthritis

A single ultrasound-guided corticosteroid and local anesthetic intra-articular hip injection offers greater pain relief to people with moderate hip osteoarthritis than the best current treatment of advice and education, research suggests.

Rituximab and rheumatology practice in the COVID-19 era

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

12-01-2022 | Osteoarthritis | News

Primary care study suggests no benefit of duloxetine for chronic osteoarthritis pain

Adding duloxetine to usual care does not improve pain outcomes for people with chronic osteoarthritis, suggest findings from a randomized controlled trial conducted in the primary care setting.

13-12-2021 | Osteoarthritis | News

Knee replacement linked to reduced MACE, mortality risk in people with osteoarthritis

People with osteoarthritis  who undergo total knee replacement may have a lower risk for major adverse cardiovascular events  and mortality than those who do not, researchers report.

14-10-2021 | Osteoarthritis | News

Network meta-analysis compares analgesic regimens for osteoarthritis

A systematic review and network meta-analysis has compared different drug treatments for pain relief in people with knee or hip osteoarthritis, finding that certain NSAIDs may have the greatest benefit, while opioids are associated with increased risk for harm.

Anifrolumab for the treatment of lupus

Anifrolumab for the treatment of SLE

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

New additions to the Adis Journal Club

Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

ACR Convergence 2021 highlights

ACR Convergence 2021

3–9 November: Keep up with the latest news and interviews from the conference.

Febuxostat and cardiovascular risk in people with gout

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

13-04-2021 | Osteoarthritis | News

Sprifermin benefits may be greatest in knee osteoarthritis patients at risk for progression

Findings from two studies suggest that sprifermin has a broadly beneficial impact on joint structure in people with knee osteoarthritis, but symptomatic efficacy may be restricted to specific patient populations.

11-02-2021 | Osteoarthritis | News

Long-term data confirm risk to joints with tanezumab

medwireNews: Long-term treatment with tanezumab is associated with an increased risk for joint-related adverse events in patients with hip or knee osteoarthritis and moderate-to-severe pain despite prior stable use of NSAIDs, phase 3 study data show.

22-01-2021 | Comorbidities | News

‘Suboptimal metabolic control’ in people with arthritis, type 2 diabetes

Patients with rheumatoid arthritis or osteoarthritis and comorbid adult-onset type 2 diabetes have a clinical profile of severe diabetes with poor glycemic control, researchers report.

NSAIDs unlikely to increase COVID-19 susceptibility in people with osteoarthritis

NSAIDs unlikely to increase COVID-19 susceptibility in people with osteoarthritis

Among patients with osteoarthritis, the risk for COVID-19 is not increased with the use of NSAIDs versus comparator analgesics, study findings indicate.

Doctor and patient in masks (symbolic image with models)

24-11-2020 | COVID-19 | News

NSAIDs unlikely to increase COVID-19 susceptibility in people with osteoarthritis

Among patients with osteoarthritis, the risk for COVID-19 is not increased with the use of NSAIDs versus comparator analgesics, study findings indicate.

Telemedicine in rheumatology

Telemedicine in rheumatology: COVID-19 and beyond

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.